MIL62

DRUG5 trials

Sponsors

Beijing Mabworks Biotech Co., Ltd.

Conditions

Neuromyelitis Optica Spectrum DisorderPrimary Membranous NephropathySystemic Lupus Erythematosus

Phase 1

A Phase Ib/ Ⅱ Clinical Study of MIL62 in Primary Membranous Nephropathy

CompletedNCT05398653

Beijing Mabworks Biotech Co., Ltd.Primary Membranous Nephropathy

Start: 2022-02-24End: 2025-04-18Updated: 2025-11-17

Phase 2

A Phase 2 Clinical Study of MIL62 in Systemic Lupus Erythematosus

Active, not recruitingNCT05796206

Beijing Mabworks Biotech Co., Ltd.Systemic Lupus Erythematosus

Start: 2023-05-26End: 2026-07-31Target: 120Updated: 2025-12-19

Phase 3

A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Active, not recruitingNCT05314010

Beijing Mabworks Biotech Co., Ltd.Neuromyelitis Optica Spectrum Disorder

Start: 2022-08-18End: 2027-03-31Updated: 2025-09-25

A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy

Active, not recruitingNCT05862233

Beijing Mabworks Biotech Co., Ltd.Primary Membranous Nephropathy

Start: 2023-06-02End: 2026-01-31Target: 150Updated: 2025-08-20

A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus

RecruitingNCT07405970

Beijing Mabworks Biotech Co., Ltd.Systemic Lupus Erythematosus

Start: 2026-04-10End: 2028-12-01Target: 316Updated: 2026-05-05

Related Papers

Obinutuzumab β for aquaporin-4-positive neuromyelitis optica spectrum disorder: a phase 3 randomized controlled trial

Nature Medicine2026-08-10

Safety and Efficacy of Obinutuzumab β (MIL62), a Novel Glycoengineered Type II Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorder: A Multicenter, Single-Arm, Phase Ib Clinical Trial.

2026-05-24

#3776 THE TYPE Ⅱ ANTI-CD20 MONOCLONAL ANTIBODY MIL62 OR CYCLOSPORINE IN CHINESE PRIMARY MEMBRANOUS NEPHROPATHY: PRELIMINARY RESULTS OF A PHASE ⅠB/Ⅱ TRIAL

Nephrology Dialysis Transplantation2023-06-01